Sentence examples for flow grading from inspiring English sources
Angiographic patency was expressed in terms of TIMI flow grading system, ECG criteria comprised extent and rapidity of ST-segment resolution, and laboratory criteria involved early peaking of CK-MB within 12 hours from randomization.
An American Society of Interventional and Therapeutic Neuroradiology/Society of Interventional Radiology Collateral Flow Grading System score of <3 on DSA.
Coronary angiography was performed to assess the extent of CAD (the number of lesions in the coronary arteries with more than 50% stenosis as well as the patency of the infarct-related artery according to TIMI flow grading system).
Angiograms were reviewed for lesion characteristics, TIMI flow grade, and degree of collateralisation.
All patients were revascularized using a coronary artery stent and obtained TIMI flow grade 3 by the end of percutaneous coronary intervention (PCI).
Coronary angiography has been used as the gold standard to define failed reperfusion, according to the Thrombolysis In Myocardial Infarction (TIMI) flow grades.
In this analysis, we observed Thrombolysis In Myocardial Infarction (TIMI) flow grade 3 or 2 in all patients, with no incidence of no-reflow.
Differences in weldability of natural compositions in the various flow grades of Lucite 129, 130, 140, 147, and 148 have not been detectable in actual applications.
However, new angiographic techniques, including the corrected TIMI frame count and myocardial blush grade, have been used to show that epicardial TIMI flow grade 3 may be an incomplete measure of reperfusion success.
Angiographic no-reflow (Thrombolysis In Myocardial Infarction [TIMI] flow grade <3 or 3 with myocardial blush grade 0 or 1 after p-PCI) was assessed immediately after p-PCI.
Initial epicardial coronary flow, as assessed by the Thrombolysis in Myocardial Infarction flow grade (TFG), prior to primary percutaneous coronary intervention (pPCI) for ST-segment elevation myocardial infarction (STEMI) has been associated with short- and long-term mortality in randomized clinical trials.
